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Among Gram-negative pathogens in Korea, the incidence of
resistance to extended-spectrum If-Iactam antibiotics is becom-
ing an ever-increasing problem in nosocomial infections [1].
The single most prevalent mechanism responsible for resistance
to If-lactam antibiotics among clinical isolates of the family
Enterobacteriaceae is the production of extended-spectrum
If-Iactamases (ESBLs). We designed 16 primer pairs from most
If-Iactamase genes belonging to four molecular classes [2]
(classes A, B, C and D) of ESBL to differentiate the genes
encoding ESBLs and to detect a new ESBL gene.
The BLASTN program at the National Center for Biotech-
nology Information was used for database searches of ESBL
genes, and the Clustal W program was used to align multiple
nucleotide sequences. Nucleotide sequence accession numbers
taken from GenBank, EMBL or DDBJ databases, and reference
reports, are available on our website: http://www.inticity.com/
ulg07100. The primers (Table 1) were designed by selecting
identical sequences in multiple nucleotide alignments of ESBL
genes and using the Primer Calculator program (Williamstone
Enterprises, Waltham, MA, USA). The electrophoretic analysis
ofpolymerase chain reaction (PCR) products ofreference genes
(blaTEM_la> blaSHV_12, blaoXA_2, blaMOX_l, blacMY_2, blaMIR_l,
blaIMP_l, blaIMI_l, and blaToho_l) showed that the fragment sizes
of PCR products were identical to those indicated in Table 1.
Using the criteria for the reduced susceptibility or resistance
to oxyimino-cephalosporins (cefotaxime and ceftazidime) and
monobactams (aztreonam) and confirmation by double disk
test, we detected five Escherichiacoli and two Klebsiella pneumo-
niae clinical isolates producing ESBLs from January 1999 to
March 1999 in Kosin Medical Center, South Korea. The
clinical isolates were recovered from urine (four strains), exu-
dates (two strains), or sputum samples (one strain). Genotypes of
ESBLs determined by PCR using plasmid DNA as a template
with 16 primer pairs included seven TEM-derived and seven
SHY-derived ESBLs. The seven clinical isolates yielded positive
results with TEM- and SHY-specific primers. Nucleotide
sequence analysis (automatic sequencer 373A; Applied Biosys-
terns, Weiterstadt, Germany) of PCR products revealed that
blaTEM_lb and blaSHV_12 were the dominant types ofIf-Iactamase
gene. In addition, we also identified blaTEM_52, blasHv_5, and a
new ESBL gene. The blaTEM_17 gene was ouly identified in
Capnocytophaga ochracea CIP 105321, a capnophilic gram-
negative fusiform rod with gliding motility [4]. Because a
new ESBL gene first detected in E. coli K992740-1 is different
from blaTEM_17 at seven positions (silent point mutations in
the coding region: C 226 ---+ T, C 436 ---+ T, A469 ---+ T, G604 ---+
T, C 682 ---+ T, T 863 ---+ C, and T 985 ---+ C), we named it
blaTEM_17b. The nucleotide sequence of blaTEM_17b has been
submitted to GenBank and assigned accession number
AF264753. PCR of blaTEM_17b containing promoter and
whole coding regions was carried out with T1' primer
(5'-CAATAACCCTGGTAAATGCT-3') and T2' primer
(5'-TTACCAATGTTTGGTAAGGGA-3'). Nucleotide sequ-
ence analysis of the PCR product showed that four mutations at
positions (according to the numbering scheme of Sutcliffe [5])
175, 226, 436 and 604 were the same as those of blaTEM_lb
(Tn-2 type) [6]. The results suggest that blaTEM_17b is harbored
in a Tn-2 type transposon. The strain containing blaTEM_17b was
resistant to ceftazidime (MIC 32 mg/L), aztreonam (MIC
64 mg/L), and amoxycillin (MIC 512 mg/L). The strain had
intermediate resistance to cefotaxime (MIC 16 mg/L) and was
susceptible to cefotetan (MIC 1 mg/L), cefoxitin (MIC 16 mg/
L), and imipenem (MIC 0.25 mg/L). The MIC profile ofE. coli
K992740-1 was similar to that of C. ochracea CIP 105321 [4].
The blaTEM_17b gene presents the single Glu104 ---+ Lys amino
acid substitution. The blaTEM_52 gene presents Glu104 ---+ Lys,
Met182 ---+ Thr and Gly238 ---+ Ser amino acid substitutions.
Therefore, the detection of blaTEM_17b suggests that
the evolution of blaTEM_52 from those genes identified
from Korean clinical isolates would seem to be
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Table 1 Nucleotide sequences of the oligonucleotides used for amplification
Gene and
primer name" Sequenceb Nucleotide position?
blaTEM
T1 5' -AGAGTATGAGTATTCAACATT- 3' 204
T2 5' -ATCTCAGCGATCTGTCTAT- 3' 1041
13 5' -AGTCACAGAAAAGCATCTTA- 3' 523
T4 5' -ATAGTTTGCGCAACGTTGT- 3' 782
blaSHV
51 5' -GGGTTATTCTTATTTGTCGCT-3' 58
52 5' -TAGCGTTGCCAGTGCTCG- 3' 987
53 5' -AGATCCACTATCGCCAGCA-3' 393
54 5' -TCATTCAGTTCCGTTTCCCA- 3' 624
blaOXA
0(10)1 5' -GTTCAATTACAGAAAATACGT- 3' 180
0(10)2 5' -TTAGCCACCAATGATGCC-3' 912
0(2)1 5' -GTTTTCCGATGGGACGG-3' 980
0(2)2 5' -ACCCATCCTACCCACCA- 3' 1361
blaCMY_> blaFQx, and blaMOX
C1 5' -GAGCAGACCCTGTTCGAGAT- 3' 570
C2 5' -GATTGGCCAGCATGACGATG-3' 1416
C3 5' -TACTCCAACCCCAGCATAGG- 3' 852
C4 5' -CCACATAGGCGCCAAAGCC- 3' 1371
blaCMY, blaAmpC[C} blaLAT,and blaBIL
CA1 5' -TGCTGCTGACAGCCTCTTTC- 3' 71
CA2 5' -TTTCAAGAATGCGCCAGGCC- 3' 1177
CA3 5' -GCGATCCGGTCACGAAATAC- 3' 359
CA4 5' -ATAACGCTGGATTTCACGCCA-3' 785
blaMIR, blaAmpC[E} and blaACT
M1 5' -CTATAAGTAAAACCTTCACCGG- 3' 1178
M2 5' -TATGCCGCCTCAACGCGTG-3' 2048
M3 5' -TGCGCTTTTATCAAAACTGGCA- 3' 1382
M4 5' -GCCACGTAGCTGCCAAACC- 3' 1967
bla,MP
11 5' -CTACCGCAGCAGAGTCTTTG- 3' 494
12 5' -ACAACCAGTTTTGCCTTACCAT- 3' 1082
bla'M' blaNM0 and blasme
IN1 5' -ATGTCATTAGGTGATATGGCT-3' 492
IN2 5' -GCATAATCATTTGCCGTACC- 3' 889
blaCTX_M and blEiraha
CT1 5' -ATCTGACGCTGGGTAAAGC- 3' 646
CT2 5' -ATATCGTTGGTGGTGCCATA- 3' 808
blapER
P1 5' -GATTTGTTATTTGAACTGGT- 3' 729
P2 5' -TGAACCTAATAACTGCATAA- 3' 1326
Expected size (bp) of
peR product (primer pair)
837 (T1 and T2)
259 (T3 and T4)
929 (51and 52)
231 (53 and 54)
732 (0(10) 1and 0(10)2)
381 (0 (2) 1and 0 (2) 2)
846 (C1and C2)
519 (C3 and C4)
1106 (CA1 and CA2)
426 (CA3 and CA4)
870 (M1 and M2)
585 (M3 and M4)
588 (11 and 12)
397 (IN1and IN2)
162 (CT1and CT2)
597 (P1and P2)
"Primers are consensus sequences of the bla genes taken from Gen Bank, EMBL, DDBJ database, orreference report (in the text). bprimersT1,T3, 51,53, 0 (10)1,
0(2)1, C1,C3, CA1, CA3, M1, M3, 11, IN1,CT1and P1 are identical to the leading strand; primersT2, T4, 52, 54, 0(10)2, 0(2)2, C2, C4, CA2, CA4, M2, M4, 12,
IN2, CT2 and P2 are identical to the lagging strand. "Numbers correspond to the position of the first 5' base of each oligonucleotide according to the number-
ing of the nucleotide sequences ofV01119 (biElrEM-1J fornT2,13 andT4; M59181 (biaSHV_1) for 51,52, 53 and 54; U37105 (biaOXA_lO) for 0(10) 1and 0 (10)2;
X07260 (biaOXA_Z) for 0 (2) 1and 0(2)2; X92508 (blaCMY_1) for C1,C2, C3 and C4; blaAmpC[C] of Citrobacter freundii [3] for CA1,CA2, CA3 and CA4; M37839
(biaMIR_1) for M1, M2, M3 and M4; 571932 (bla,MP_1) for 11 and 12;U50278 (bla,MI_1) for IN1and IN2; X92506 (blaCTX-M-1) for CT1and CT2; Z21957 (biapER_1) for
P1 and P2.
blaTEM_lb ---+ blaTEM_17b ---+ a novel If-Iactamase gene
(Glu104 ---+ Lys plus Met182 ---+ Thr or Met182 ---+ Thr plus
Gly238 ---+ Ser) ---+ blaTEM_52, although the novel If-Iactamase
gene has not been identified (http://www.lahey.org/studies/
webt.htm). Furthermore, blaTEM_lb (E. coli K992806-2),
blaTEM_17b (E. coli K992740-1) and blaTEM_52 (K. pneumoniae
K992806-3) were detected in the different samples of one
patient (1-year-old baby). E. coli K992806-2 and E. coli
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K992740-1 had intermediate resistance to cefotaxime (MIC
16 mg/L), whereas K. pneumoniae K992806-3 was resistant to
cefotaxime (MIC 64 mg/L). Three strains were resistant to
ceftazidime and aztreonam, but the MICs were higher in E. coli
K992806-2, E. coliK992740-1, and K. pneumoniae K992806-3,
in that order. Sequence analysis revealed that blaTEM_17b was
more similar to blaTEM_lb than to blaTEM_la> and four of
seven silent mutations of blaTEM_17b were the same as those
of blaTEM_52 (at positions 469, 682, 863 and 985). Our findings
from the same patient appear to represent the in vivo evolution
of If-Iactamase genes (from blaTEM_lb to blaTEM_17b and from
blaTEM_17b to blaTEM_52) under the selective pressure of anti-
microbial therapy (especially cefotaxime), as was the case with
blasHv_8 [7].
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Rhodotorula, a yeast member ofthe family Cryptococcaceae, was
only recently recognized as a human pathogen especially affect-
ing immunocompromised patients [1]. To our knowledge, over
the last 40 years, no more than 40 cases ofrhodotornla infections
have been reported in patients with central indwelling vascnlar
catheters. We isolated Rhodotorula rubra from both the catheter
and the peripheral venous blood of a patient on azole prophy-
laxis. On this occasion, we reviewed the literature and the
limited experience with rhodo torula hospital infections in
Greece.
A 21-year-old female patient, with non-Hodgkin's lym-
phoma in second remission, underwent autologous peripheral
blood progenitor cell transplantation. A large peripheral
double lumen catheter was placed in the subclavian vein for
the collection and reinfusion of stem cells. The conditioning
regImen was gIven on days - 5 to - 1. The patient
received prophylactic oral ciprofloxacin 500 mg twice daily
and fluconazole 200 mg/day. Because of severe vomiting and
gastrointestinal mucositis, total parenteral nutrition was man-
datory. One day after stem cell reinfusion (day 1), the patient
developed grade 4 neutropenia on the WHO toxicity scale
(PMN count <100/IlL), and 3 days later (9 days after insertion
of the catheter) she became febrile. Blood cultures were
obtained from both the catheter sites as well as from the
antecubital vein. Ciprofloxacin was discontinued, and intrave-
nous ceftazidime, vancomycin and amikacin were started.
Microscopic examination ofall blood cnltures revealed budding
yeasts.
Blood cnltures were performed with the continuously mon-
itored non-invasive system BACTEC 9240 (Becton Dickinson
Medical Systems, Rutherford, NJ, USA). Blood specimens
were inoculated in BACTEC plus F aerobic and anaerobic
bottles (Becton Dickinson Microbiology Systems, Sporks,
Maryland, USA) and were incubated for a standard 7-day
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